Sakar Healthcare Limited — Investor Meet, 03-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Sakar Healthcare delivered strong Q1 FY27 financial results: Revenue at INR72.97 Cr (up 38% YoY), EBITDA at INR21.25 Cr (up 67% YoY) with 29% margins, and PAT at INR10.28 Cr (up 120% YoY). The company is rapidly transforming into an oncology-led export powerhouse. It has 55 oncology molecules developed and 32 dossiers ready, with 178 global dossier submissions and 16 marketing authorizations received, targeting major markets. Oncology revenue guidance is to double FY26 levels this year and triple by FY28, with EBITDA margins set to cross 30% soon and 35%+ with API integration. Management is confident in robust export growth and operational leverage from its EU-GMP Bavla facility.